In a recent trial designed for patients newly diagnosed with AML ineligible for standard induction chemotherapy, azacitidine plus venetoclax was superior to azacitidine alone, also in the subset of IDH1/IDH2- and TP53-mutated patients [146]. Here, IDH1 is linked to acute myeloid leukemia.